Latest press articles and news about NovaScan and our innovative cancer detection technology.
NovaScan Press ReleaseApr 14, 2026
NovaScan Appoints Bob Cook as Chief Operating Officer to Accelerate Commercialization of MarginScan™ Platform
NovaScan, Inc. announced the appointment of Robert W Cook, PhD as Chief Operating Officer. Cook, formerly Senior Vice President of Research and Development at Castle Biosciences, will oversee operational execution, commercialization strategy, and market access as NovaScan prepares the clinical and commercial launch of its MarginScan™ platform.
NovaScan Awarded $3.7 Million CPRIT Grant to Advance MarginScan™ for Breast Cancer Surgery
NovaScan, Inc. announced that it has been awarded a $3.7 million non-dilutive grant from the Cancer Prevention and Research Institute of Texas (CPRIT). The funding will support clinical work and deployment of MarginScan™ for use in breast-conserving surgery.
Study Involving NovaScan's Groundbreaking MarginScan™ Intraoperative Cancer Device Selected for Presentation at 2025 AAD Innovation Academy
NovaScan's research on rapid margin assessment using high-frequency bioelectrical impedance spectroscopy during Mohs micrographic surgery has been selected by the American Academy of Dermatology for its prestigious "Future of Dermatology" session.
Clinical Results with NovaScan MarginScan™ Device to be Presented at Wisconsin Dermatology Society Meeting
NovaScan's MarginScan™ device will be featured in a poster presentation at the Wisconsin Dermatology Society Spring Meeting, highlighting the clinical performance of MarginScan in real-time surgical margin detection.
NovaScan Announces a New Pancreatic Trial at the University of Illinois Medical Center
A new clinical trial has started employing the NovaScan Canary biopsy assessment device to detect developing pancreatic cancers in high-risk populations, focusing on patients with chronic pancreatitis who have not yet developed cancer.
NovaScan Announces the Appointment of Two Luminary Advisors
NovaScan announced the appointment of Robert W. Cook, Ph.D., former senior vice president of research and development at Castle Biosciences, and Robert Zieserl, a serial entrepreneur and venture capitalist, as advisors to assist the company as it advances towards commercialization.